
IHC-P analysis of human brain tissue using GTX34362 EID1 antibody. Negative control (the lower left coner) was secondary antibody only. Antigen retrieval : Tris-EDTA, pH8.0 under high-pressure and temperature Dilution : 1:100
EID1 antibody
GTX34362
ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman
TargetEID1
Overview
- SupplierGeneTex
- Product NameEID1 antibody
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:2000. IHC-P: 1:100-1:300. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration1 mg/ml
- ConjugateUnconjugated
- Gene ID23741
- Target nameEID1
- Target descriptionEP300 interacting inhibitor of differentiation 1
- Target synonymsC15orf3, CRI1, EID-1, IRO45620, PNAS-22, PTD014, RBP21, EP300-interacting inhibitor of differentiation 1, 21 kDa pRb-associated protein, CREBBP/EP300 inhibitor 1, CREBBP/EP300 inhibitory protein 1, E1A-like inhibitor of differentiation 1, NB4 apoptosis related protein, Rb- and p300-binding protein EID-1, retinoblastoma protein-associated protein
- HostRabbit
- IsotypeIgG
- Protein IDQ9Y6B2
- Protein NameEP300-interacting inhibitor of differentiation 1
- ReactivityHuman
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203



![ICC/IF analysis of HeLa cells using GTX00708 EID1 antibody [clone 2]. Red : Primary antibody Green : DAPI Dilution : 1:1000 Fixation : 4% PFA, overnight Permeabilization : 0.25% Triton X-100 in PBS for 10 min](https://www.genetex.com/upload/website/prouct_img/normal/GTX00708/GTX00708_20191104_ICC-IF_w_23053121_720.webp)
![ICC/IF analysis of HeLa cells using GTX00710 EID1 antibody [clone 26]. Dilution : 1:1000 Fixation : 4% PFA, overnight Permeabilization : 0.25% Triton X-100 in PBS for 10 min](https://www.genetex.com/upload/website/prouct_img/normal/GTX00710/GTX00710_20191104_ICC-IF_w_23053121_680.webp)



